Medigene (XTRA:MDG1) - Share price, News & Analysis

MDG1 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

MDG1 Stock Overview

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer.

Risk Analysis

Earnings are forecast to decline by an average of 37% per year for the next 3 years

Does not have a meaningful market cap (€64M)

Medigene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medigene
Historical stock prices
Current Share Price	€2.61
52 Week High	€4.59
52 Week Low	€1.90
Beta	1.05
1 Month Change	-11.22%
3 Month Change	-30.40%
1 Year Change	-32.91%
3 Year Change	-67.84%
5 Year Change	-75.90%
Change since IPO	-99.05%

Recent News & Updates

Mar 24

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

	MDG1	DE Biotechs	DE Market
7D	-3.7%	1.2%	-0.4%
1Y	-32.9%	-32.7%	-12.4%

Return vs Industry: MDG1 underperformed the German Biotechs industry which returned -31.4% over the past year.

Return vs Market: MDG1 underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is MDG1's price volatile compared to industry and market?
MDG1 volatility
MDG1 Average Weekly Movement	7.9%
Biotechs Industry Average Movement	7.9%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	10.6%
10% least volatile stocks in DE Market	3.4%

Stable Share Price: MDG1 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MDG1's weekly volatility has decreased from 15% to 8% over the past year.

About the Company

Founded	Employees	CEO	Website
1994	58	Dolores Schendel	https://www.medigene.com

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies.

Medigene Fundamentals Summary

How do Medigene's earnings and revenue compare to its market cap?
MDG1 fundamental statistics
Market Cap	€64.11m
Earnings (TTM)	-€9.98m
Revenue (TTM)	€10.46m

6.1x

P/S Ratio

-6.4x

P/E Ratio

Is MDG1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDG1 income statement (TTM)
Revenue	€10.46m
Cost of Revenue	€1.36m
Gross Profit	€9.10m
Other Expenses	€19.09m
Earnings	-€9.98m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 03, 2022

Earnings per share (EPS)	-0.41
Gross Margin	87.00%
Net Profit Margin	-95.41%
Debt/Equity Ratio	0%

How did MDG1 perform over the long term?

See historical performance and comparison

Valuation

Is Medigene undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.43x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: MDG1 is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: MDG1 is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDG1's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MDG1 is good value based on its PB Ratio (1.4x) compared to the DE Biotechs industry average (1.5x).

Future Growth

How is Medigene forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-37.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDG1's earnings are forecast to decline over the next 3 years (-37% per year).

Earnings vs Market: MDG1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDG1's is expected to become profitable in the next 3 years.

Revenue vs Market: MDG1's revenue is expected to decline over the next 3 years (-16.1% per year).

High Growth Revenue: MDG1's revenue is forecast to decline over the next 3 years (-16.1% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MDG1's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Medigene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-8.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDG1 is currently unprofitable.

Growing Profit Margin: MDG1 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MDG1 is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.

Accelerating Growth: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: MDG1 has a negative Return on Equity (-22.28%), as it is currently unprofitable.

Financial Health

How is Medigene's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDG1's short term assets (€24.2M) exceed its short term liabilities (€8.0M).

Long Term Liabilities: MDG1's short term assets (€24.2M) exceed its long term liabilities (€6.6M).

Debt to Equity History and Analysis

Debt Level: MDG1 is debt free.

Reducing Debt: MDG1 had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDG1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MDG1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Medigene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDG1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDG1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDG1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDG1's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDG1 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure

CEO

Dolores Schendel

8yrs

Tenure

€395,000

Compensation

Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief...

CEO Compensation Analysis

Compensation vs Market: Dolores's total compensation ($USD422.10K) is about average for companies of similar size in the German market ($USD404.30K).

Compensation vs Earnings: Dolores's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: MDG1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: MDG1's board of directors are considered experienced (4.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31